Jones Mitchell Lawrence 4
4 · PALISADE BIO, INC. · Filed May 30, 2024
Insider Transaction Report
Form 4
Jones Mitchell Lawrence
Chief Medical Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2024-05-28−1,555→ 0 total→ Common Stock (1,555 underlying) - Exercise/Conversion
Common Stock, par value $0.01
2024-05-28+2,735→ 3,568 total - Exercise/Conversion
Common Stock, par value $0.01
2024-05-28+1,555→ 4,313 total - Exercise/Conversion
Restricted Stock Units
2024-05-28−2,735→ 0 total→ Common Stock (2,735 underlying) - Tax Payment
Common Stock, par value $0.01
2024-05-28$4.76/sh−810$3,856→ 2,758 total - Tax Payment
Common Stock, par value $0.01
2024-05-28$4.76/sh−461$2,194→ 3,852 total
Footnotes (7)
- [F1]Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on September 5, 2023.
- [F2]Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 1.
- [F3]Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023.
- [F4]Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 3.
- [F5]Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- [F6]This restricted stock unit was granted on September 5, 2023, and all remaining 2,735 restricted stock units subject to the award were accelerated and vested on May 28, 2024 by the Compensation Committee of the Issuer.
- [F7]This restricted stock unit was granted on November 21 2024, and all remaining 1,555 restricted stock units subject to the award were accelerated and vested on May 28, 2024 by the Compensation Committee of the Issuer.